

Current report 7/2021
18 March, 2021 r.

Conclusion of the grant agreement with the National Center for Research and Development

Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow ("Company"), with reference to the current report 4/2021, hereby announces that on March 17, 2021 Company obtained information about the conclusion of the grant agreement with the National Center for Research and Development (NCBiR) for the project titled "Clinical development of an innovative drug candidate in solid tumors" ("Project") within the Smart Growth Operational Programme 2014-2020, measure 1.1.1. "Fast Track".

The goal of the Project is implementation into Ryvu Therapeutics S.A. business a new drug candidate – inhibitor of CDK8/19 kinases, evaluated in I/II clinical phase (until stage of dose expansion). It should overcome the limitations of current treatment options benefitting patients with most aggressive solid tumors who have exhausted therapeutic possibilities.

- Project net value: PLN 42 696 464;
- Financing granted: PLN 18 939 762.79;
- Project timeline: September 2020 - December 2023.

Legal basis: Article 17(1) of the Market Abuse Regulation (MAR) – confidential information.

Represented by:

- Setareh Shamsili – Vice President of the Management Board
- Tomasz Nocuń – Proxy